The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells

Nature Genetics

Volumn 44, Issue 8, 2012, Pages 861-871

  Zhang, Haojian ^a   Peng, Cong ^a   Hu, Yiguo ^b   Li, Huawei ^a   Sheng, Zhi ^a   Chen, Yaoyu ^a   Sullivan, Con ^c   Cerny, Jan ^a   Hutchinson, Lloyd ^d   Higgins, Anne ^d   Miron, Patricia ^d   Zhang, Xueqing ^a   Brehm, Michael A ^a   Li, Dongguang ^e   Green, Michael R ^a   Li, Shaoguang ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MAINE   (United States)

^d UMASS MEMORIAL MEDICAL CENTER   (United States)

^e EDITH COWAN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BLK PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; HEMATOPOIESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENES, ABL; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANS-ACTIVATORS; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 84864403159     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2350     Document Type: Article

References (59)

1. Huntly, B.J. & Gilliland, D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer 5, 311-321 (2005).
2. Reya, T., Morrison, S.J., Clarke, M.F. & Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
3. Visvader, J.E. & Lindeman, G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
4. Wang, J.C. & Dick, J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494-501 (2005).
5. Chen, Y., Hu, Y., Zhang, H., Peng, C. & Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 41, 783-792 (2009).
6. Hu, Y. et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. USA 103, 16870-16875 (2006).
7. Melo, J.V. & Barnes, D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7, 441-453 (2007).
8. Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172-183 (2005).
9. Wong, S. & Witte, O.N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247-306 (2004).
10. Druker, B.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
11. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
12. Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006).
13. Graham, S.M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002).
14. Corbin, A.S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396-409 (2011).
15. Lessard, J. & Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255-260 (2003).
16. Park, I.K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302-305 (2003).
17. Saijo, K. et al. Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development. Nat. Immunol. 4, 274-279 (2003).
18. Zwollo, P. & Desiderio, S. Specific recognition of the blk promoter by the B-lymphoid transcription factor B-cell-specific activator protein. J. Biol. Chem. 269, 15310-15317 (1994).
19. Nutt, S.L., Heavey, B., Rolink, A.G. & Busslinger, M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556-562 (1999).
20. Xie, S., Lin, H., Sun, T. & Arlinghaus, R.B. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21, 7137-7146 (2002).
21. Sawyers, C.L., Callahan, W. & Witte, O.N. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70, 901-910 (1992).
22. Notari, M. et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 107, 2507-2516 (2006).
23. O'Riordan, M. & Grosschedl, R. Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity 11, 21-31 (1999).
24. Lin, H. & Grosschedl, R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature 376, 263-267 (1995).
25. Wang, H. et al. IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood 112, 4028-4038 (2008).
26. Wang, H. & Morse, H.C. III. IRF8 regulates myeloid and B lymphoid lineage diversification. Immunol. Res. 43, 109-117 (2009).
27. Xia, Z.B. et al. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc. Natl. Acad. Sci. USA 102, 14028-14033 (2005).
28. Andreu, E.J. et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 65, 3264-3272 (2005).
29. Chu, I. et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128, 281-294 (2007).
30. Grimmler, M. et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 128, 269-280 (2007).
31. Jonuleit, T. et al. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 96, 1933-1939 (2000).
32. Rangatia, J. & Bonnet, D. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 20, 68-76 (2006).
33. Oda, H., Kumar, S. & Howley, P.M. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc. Natl. Acad. Sci. USA 96, 9557-9562 (1999).
34. Frescas, D. & Pagano, M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 8, 438-449 (2008).
35. Agarwal, A. et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 112, 1960-1970 (2008).
36. Radich, J.P. et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 103, 2794-2799 (2006).
37. Zhang, B. et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427-442 (2010).
38. Affer, M. et al. Gene expression differences between enriched normal and chronic myelogenous leukemia quiescent stem/progenitor cells and correlations with biological abnormalities. J. Oncol. 2011, 798592 (2011).
39. Nordon, R.E., Ginsberg, S.S. & Eaves, C.J. High-resolution cell division tracking demonstrates the FLt3-ligand-dependence of human marrow CD34+CD38?cell production in vitro. Br. J. Haematol. 98, 528-539 (1997).
40. Heaney, N.B. et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 115, 2241-2250 (2010).
41. Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003).
42. Dierks, C. et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238-249 (2008).
43. Kirstetter, P., Anderson, K., Porse, B.T., Jacobsen, S.E. & Nerlov, C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat. Immunol. 7, 1048-1056 (2006).
44. Scheller, M. et al. Hematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation. Nat. Immunol. 7, 1037-1047 (2006).
45. Zhao, C. et al. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12, 528-541 (2007).
46. Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779 (2009).
47. Hu, Y., Chen, Y., Douglas, L. & Li, S. β-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 23, 109-116 (2009).
48. Hu, Y. et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36, 453-461 (2004).
49. Warmuth, M. et al. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J. Biol. Chem. 272, 33260-33270 (1997).
50. Wu, J. et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111, 3821-3829 (2008).
51. Xiao, W., Hong, H., Kawakami, Y., Lowell, C.A. & Kawakami, T. Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J. Clin. Invest. 118, 924-934 (2008).
52. Cobaleda, C., Schebesta, A., Delogu, A. & Busslinger, M. Pax5: the guardian of B cell identity and function. Nat. Immunol. 8, 463-470 (2007).
53. Mullighan, C.G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007).
54. Mullighan, C.G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470-480 (2009).
55. Cheng, T., Rodrigues, N., Dombkowski, D., Stier, S. & Scadden, D.T. Stem cell repopulation efficiency but not pool size is governed by p27kip1. Nat. Med. 6, 1235-1240 (2000).
56. Ramaraj, P. et al. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res. 64, 5322-5331 (2004).
57. Copland, M. et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111, 2843-2853 (2008).
58. Li, S., Ilaria, R.L. Jr., Million, R.P., Daley, G.Q. & Van Etten, R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399-1412 (1999).
59. Peng, C. et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110, 678-685 (2007).